PubRank

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (ADIRAS)

Clinical Trial ID NCT01444833

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01444833

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 25.54
2 Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003 5.08
3 Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000 3.63
4 Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004 3.51
5 Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000 3.40
6 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001 2.69
7 Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004 2.51
8 Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004 2.11
9 Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 2002 1.79
10 Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005 1.71
11 Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002 1.70
12 Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun 2004 1.65
13 The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003 1.65
14 Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004 1.64
15 Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003 1.62
16 Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003 1.50
17 A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002 1.40
18 Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006 1.40
19 Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005 1.37
20 Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2003 1.23
21 Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998 1.22
22 Secretory, endocrine and autocrine/paracrine function of the adipocyte. J Nutr 2000 1.18
23 Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 2004 1.13
24 Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2006 1.10
25 Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999 1.03
26 ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2006 1.00
27 Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 2003 0.98
28 Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002 0.98
29 TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007 0.98
30 Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 2007 0.91
31 Partial characterization of insulin resistance in adipose tissue of monosodium glutamate-induced obese rats. Ann N Y Acad Sci 1997 0.89
32 Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol 1994 0.82
33 Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism 1998 0.82
34 Rat epididymal fat tissue express all components of the renin-angiotensin system. Gen Physiol Biophys 2000 0.82
35 The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys 1995 0.81
36 Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007 0.79
37 Hypertension and diabetes. J Hum Hypertens 2002 0.78
38 Elevated AT1 receptor protein but lower angiotensin II-binding in adipose tissue of rats with monosodium glutamate-induced obesity. Horm Metab Res 2001 0.78
39 The alterations in insulin sensitivity during angiotensin converting enzyme inhibitor treatment are related to changes in the calcium/magnesium balance. Am J Hypertens 1997 0.76
40 Circulating catecholamines and metabolic effects of captopril in NIDDM patients. Diabetes Care 1996 0.76
41 Effect of angiotensin-converting enzyme inhibition on renal norepinephrine spillover rate and baroreflex responses in conscious rabbits. Clin Exp Pharmacol Physiol 1991 0.75
Next 100